




RealRate

PHARMACEUTICAL 2018

Alder Biopharmaceuticals INC
Rank 135 of 332



The relative strengths and weaknesses of Alder Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alder Biopharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 118% points. The greatest weakness of Alder Biopharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 300%, being 48% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	287,254
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,366
Liabilities, Non-Current	0
Other Assets	10,252
Other Compr. Net Income	-44
Other Expenses	1,619
Other Liabilities	495
Other Net Income	3,744
Other Revenues	0
Property and Equipment	5,630
Research and Development	252,902
Selling, General and Administrative Expense	38,102

Output Variable	Value in 1000 USD
Assets	303,136
Liabilities	23,861
Expenses	292,623
Revenues	0
Stockholders Equity	279,275
Net Income	-288,879
Comprehensive Net Income	-288,901
BaseVar	311,704
ECR before LimitedLiability	196%
Economic Capital Ratio	300%